chemic
tool
exist
directli
studi
therebi
elucid
function
pld
enzym
small
molecul
avail
dissect
individu
role
two
main
mammalian
pld
isoenzym
therapeut
relev
pld
enzym
endocannabinoid
regul
nacyl
phosphatidylethanolaminespecif
phospholipas
napepld
bacteri
histor
field
reli
overexpress
catalyt
activ
inact
form
enzym
question
block
express
use
rnamedi
interfer
rnai
howev
biochem
genet
approach
littl
garner
attent
pharmaceut
pld
inhibit
emerg
viabl
therapeut
approach
target
valid
select
small
molecul
requir
although
earli
effort
throughout
identifi
small
molecul
capabl
modul
function
pld
indirectli
exampl
polyphenol
natur
product
resveratrol
fig
compound
steroid
triptolid
fig
compound
directli
phosphat
mimet
tungstat
fig
compound
vanad
fig
compound
well
natur
product
fig
compound
calphostin
c
fig
compound
ligand
fail
acceler
develop
field
part
owe
obviou
lack
specif
thu
past
year
commonli
use
class
molecul
studi
function
pld
enzym
primari
alcohol
exampl
nbutanol
fig
compound
emphas
alcohol
nbutanol
block
pldcatalys
ptdoh
product
compet
water
nucleophil
howev
blockad
ptdoh
product
frequent
incomplet
experiment
condit
thu
caution
must
exercis
interpret
data
studi
use
primari
alcohol
decad
fals
start
brief
report
publish
group
novarti
describ
halopemid
fig
compound
concentr
inhibit
activ
set
analogu
inhibitor
analogu
includ
indol
amid
congen
refer
deschlorohalopemid
fipi
fig
compound
nm
manuscript
report
activ
mention
inhibit
prompt
pharmacolog
evalu
compound
cellbas
biochem
assay
purifi
interestingli
halopemid
potent
inhibit
cellular
nm
biochem
nm
cellular
nm
biochem
nm
fipi
cellular
nm
biochem
nm
cellular
nm
biochem
nm
therefor
halopemid
report
accur
describ
dual
inhibitor
although
isoenzym
select
remain
elus
discoveri
inform
lead
halopemid
origin
develop
janssen
atyp
antipsychot
potent
antagonist
activ
dopamin
receptor
well
addit
biogen
amin
receptor
call
psychic
energ
ref
clinic
trial
halopemid
shown
effect
neg
well
posit
symptom
schizophrenia
without
extrapyramid
side
effect
common
standard
atyp
antipsychot
importantli
halopemid
achiev
high
plasma
exposur
display
advers
event
abnorm
biochemistri
exposur
halopemid
fulli
inhibit
suggest
mechan
inhibit
chemotyp
would
safe
human
repres
major
step
toward
derisk
therapeut
approach
howev
halopemid
panacea
mani
laboratori
began
use
halopemid
fipi
key
proofofconcept
tool
target
valid
led
potenti
flaw
conclus
compound
display
consider
amount
ancillari
pharmacolog
multitud
biogen
amin
receptor
expect
atyp
antipsychot
gpcrprivileg
structur
core
thu
initi
optim
programm
use
halopemid
one
start
point
develop
isoenzymeselect
pld
inhibitor
improv
ancillari
pharmacolog
drug
metabol
pharmacokinet
dmpk
profil
suitabl
vivo
proofofconcept
design
optim
strategi
base
result
two
type
vitro
catalyt
assay
conduct
parallel
cellbas
assay
biochem
assay
present
defin
substrat
human
rat
recombin
pld
combin
diversityori
synthesi
matrix
librari
subsequ
iter
parallel
synthesi
analogu
prepar
assay
lead
seri
first
highli
inhibitor
exemplifi
fig
compound
nm
select
versu
ref
fig
instanc
addit
methyl
group
ethyl
linker
increas
select
versu
across
multipl
exampl
subseri
diminish
activ
enhanc
inhibitori
activ
fig
virtu
methyl
group
multitud
result
analogu
display
select
within
tradit
unanticip
find
strike
exampl
magic
methyl
effect
modif
linker
promot
ushap
ligand
topolog
importantli
markedli
improv
ancillari
pharmacolog
rel
halopemid
fipi
display
attract
dmpk
profil
enabl
vivo
proofofconcept
within
piperidin
benzimidazolon
core
analogu
prefer
elus
thu
number
bioisoster
piperidin
benzimidazolon
well
altern
gpcrprivileg
structur
relationship
sar
compound
shallow
variant
studi
devoid
pldinhibitori
activ
howev
nphenyl
triazaspiron
congen
fig
compound
display
modest
prefer
repres
consider
departur
halopemidebas
pld
subsequ
lead
optim
campaign
focus
nphenyl
triazaspiron
congen
encount
shallow
sar
yet
addit
fluorin
atom
threeposit
nphenyl
moieti
provid
fig
compound
first
highli
select
inhibitor
nm
select
versu
moreov
similarli
direct
pld
inhibitor
potent
activ
biochem
assay
purifi
pld
protein
addit
improv
ancillari
pharmacolog
rel
halopemid
fipi
dmpk
profil
suitabl
vivo
proofofconcept
interestingli
peripher
restrict
wherea
cn
penetr
braintoplasma
ratio
kp
intrigu
observ
within
novel
seri
relat
effect
methyl
group
mark
impact
select
benzimidazolon
seri
benzimidazolon
seri
addit
methyl
group
nphenyl
triazaspiron
congen
convert
approxim
tenfold
inhibitor
dual
inhibitor
compound
fig
approxim
sixfold
select
versu
subtl
structur
featur
promot
substanti
chang
pld
isoform
select
reminisc
molecular
switch
preval
alloster
gpcr
unpreced
level
pld
isoenzym
select
presenc
appar
molecular
switch
led
us
question
mechan
compound
inhibit
pld
enzym
featur
along
structur
similar
compound
previous
report
piperidin
benzimidazolonebas
alloster
inhibitor
twosit
bind
mode
within
catalyt
domain
pleckstrin
homolog
domain
led
us
postul
alloster
initi
studi
halopemid
fipi
assay
use
truncat
construct
lack
portion
pleckstrin
homolog
domain
show
slight
reduct
pld
howev
significantli
reduc
pld
activ
tenfold
suggest
pleckstrin
homolog
domain
domain
far
away
hkd
catalyt
activ
site
key
bind
molecul
addit
enzym
kinet
studi
increas
confid
compound
use
backscatt
interferometri
found
bind
two
site
protein
one
high
affin
low
affin
support
alloster
mode
inhibit
akin
alloster
akt
cours
absenc
highresolut
structur
determin
site
interact
somewhat
specul
suggest
report
evid
publish
two
site
inhibitor
action
involv
enzym
catalyt
centr
alloster
phosphoinositidebind
studi
fipi
shown
interact
also
pld
isoenzym
contrast
interact
two
differ
site
one
hkd
alloster
site
nativ
occupi
phosphatidylinositol
pi
bind
alloster
site
block
pi
bind
combin
pi
site
form
hydrophob
pocket
pleckstrin
homolog
domain
ident
alloster
akt
thu
promot
high
degre
secondgener
halopemidebas
triazaspironebas
pld
inhibitor
achiev
high
select
individu
isoenzym
also
provid
novel
alloster
mechan
pld
recent
emerg
target
oncolog
infecti
serv
proofofconcept
howev
better
tool
requir
although
select
select
driven
potenc
nm
compound
still
inhibit
modest
concentr
nm
therefor
thirdgener
optim
campaign
effort
led
synthesi
fig
compound
select
nm
neglig
activ
incorpor
methyl
group
use
piperidin
benzimidazolon
seri
substanti
impact
enhanc
inhibitori
activ
increas
provid
fig
compound
potent
dual
inhibitor
nm
nm
ancillari
pharmacolog
physiochem
properti
improv
interestingli
found
peripher
restrict
wherea
cn
penetr
kp
base
abil
triazaspiron
core
provid
rang
pld
pharmacolog
profil
varieti
nonnar
aromat
moieti
bound
nitrogen
evalu
attempt
develop
inhibitor
compar
cn
effort
identifi
fig
compound
pyridylmethyl
congen
good
potenc
nm
measur
activ
except
physiochem
properti
excel
dmpk
profil
includ
high
cn
penetr
kp
result
seri
potent
isoenzymeselect
well
dual
pld
inhibitor
develop
compound
dmpk
ancillari
pharmacolog
profil
suitabl
vivo
proofofconcept
experi
aim
dissect
role
individu
mammalian
pld
enzym
describ
although
major
advanc
pld
field
halopemidederiv
novel
triazaspironebas
seri
mammalian
pld
inhibitor
devoid
activ
bacteri
pseudomona
aeruginosa
plda
endocannabinoid
regul
importantli
ligand
exist
could
modul
structur
diverg
pld
enzym
thu
hinder
understand
potenti
therapeut
agent
search
inhibitor
pld
enzym
led
reexamin
certain
select
oestrogen
receptor
modul
serm
use
success
treatment
oestrogenreceptorposit
breast
previou
report
suggest
potenti
erindepend
mechan
efficaci
serm
raloxifen
fig
compound
fig
compound
activ
metabolit
tamoxifen
compound
may
due
offtarget
inhibit
mammalian
pld
potenti
serm
chemotyp
pld
inhibitor
fulli
explor
recent
part
pldinhibitori
activ
requir
midmicromolar
concentr
serm
activ
might
complic
definit
target
valid
howev
novel
chemotyp
might
provid
novel
scaffold
could
achiev
univers
pld
inhibit
across
divers
pld
enzym
bind
mode
distinct
halopemidederiv
triazaspironebas
seri
mammalian
pld
intriguingli
raloxifen
tamoxifen
show
modest
inhibitori
activ
bacteri
plda
enzym
prompt
evalu
desketoraloxifen
fig
compound
serm
uniqu
planar
topolog
stronger
activ
activ
protein
bind
site
encod
oestrogen
compar
encod
oestrogen
desketoraloxifen
breakthrough
compar
inhibitori
activ
mammalian
mammalian
bacteri
plda
fig
unexpect
find
led
new
multidimension
optim
campaign
focus
desketoraloxifen
produc
hundr
novel
analogu
take
account
wellestablish
serm
pharmacophor
model
analogu
design
abolish
serm
activ
fig
measur
use
vitro
enzymat
assay
plda
effort
provid
compound
fig
devoid
moieti
crucial
oestrogen
receptor
bind
antiprolif
action
also
contain
n
ndimethylamino
moieti
known
greatli
reduc
serm
activ
retain
good
activ
plda
even
napepld
find
also
led
profil
desketoraloxifen
napepld
found
slightli
potent
compound
napepld
thu
desketoraloxifen
compound
repres
first
entri
potenti
univers
inhibit
structur
phylogenet
distinct
pld
although
advanc
compound
lead
compound
halopemid
mammalian
chemotyp
develop
optim
compound
target
valid
plda
napepld
strateg
use
divers
interdisciplinari
experiment
approach
includ
lipidom
metabolom
phosphoproteom
medicin
chemistri
molecular
pharmacolog
biochemistri
dmpk
optim
led
develop
select
compound
allow
role
individu
mammalian
isoenzym
dissect
uncov
alloster
mechan
inhibit
provid
entri
chemotyp
provid
potenti
univers
pld
inhibit
compound
provid
initi
start
point
develop
inhibitor
plda
napepld
develop
compound
offer
new
set
tool
analys
role
pld
enzym
gener
specif
pld
isoenzym
divers
biolog
condit
although
earli
work
describ
implic
pld
enzym
number
normal
patholog
process
select
provid
compound
allow
direct
interrog
host
respons
infecti
diseas
includ
influenza
viru
hiv
infect
cancer
although
genet
approach
includ
induc
knockout
system
advantag
achiev
complet
delet
enzym
activ
highli
select
compound
use
divers
cell
type
anim
model
includ
genet
ablat
difficult
addit
delet
pld
enzym
like
effect
distinct
shortterm
inhibit
latter
provid
better
model
therapeut
intervent
virus
coopt
resourc
target
host
complet
replic
cycl
parasit
includ
use
cellular
process
metabolit
resourc
pool
everi
stage
viru
life
cycl
requir
host
cell
cooper
viru
entri
often
exploit
hostcel
traffick
pathway
endosom
format
nucleic
acid
transport
replic
protein
product
protein
traffick
modif
final
culmin
viral
bud
host
cell
energi
nucleic
acid
amino
acid
lipid
ingredi
product
new
viru
particl
pld
enzym
influenc
pathway
directli
role
pld
enzym
gener
ptdoh
make
key
compon
nascent
small
endosom
use
entri
mani
virus
includ
influenza
viru
respiratori
syncyti
viru
hepat
c
viru
ptdoh
enrich
endosom
membran
requir
membran
although
yet
directli
demonstr
inhibit
pld
enzym
could
potenti
limit
effici
endosom
format
provid
earli
block
viru
replic
cycl
furthermor
activ
pld
enzym
product
ptdoh
support
multipl
signal
transduct
cascad
includ
mediat
mitogenactiv
protein
kinas
mapk
exampl
shown
necessari
activ
earli
endosom
traffick
molecul
earli
endosom
antigen
make
use
extens
librari
avail
compound
inhibit
divers
form
pld
studi
undertaken
dissect
role
pld
enzym
host
respons
infecti
diseas
includ
influenza
viru
hiv
role
pathogen
pld
enzym
specif
bacteri
infect
influenza
viru
potenti
role
pld
enzym
crucial
event
viru
life
cycl
led
us
investig
function
enzym
influenza
viru
inde
follow
challeng
host
cell
influenza
viru
vitro
pld
catalyt
activ
markedli
increas
measur
increas
ptdbuoh
mass
pretreat
respiratori
epitheli
cell
primari
alcohol
rnai
target
result
signific
decreas
number
cell
infect
influenza
viru
infecti
titr
produc
cultur
panel
smallmolecul
pld
inhibitor
test
similar
assay
isoformspecif
inhibitor
includ
potent
antivir
activ
vitro
experi
compound
inhibit
cellular
infect
viral
replic
rang
clinic
relev
influenza
virus
pandem
influenza
viru
strain
recent
emerg
avian
influenza
viru
strain
repres
highli
pathogen
influenza
viru
addit
cultur
medium
revers
accumul
ptdbuoh
influenza
virusinfect
cell
indic
catalyt
activ
role
influenza
viru
prophylact
treatment
provid
signific
protect
mous
model
lethal
challeng
sever
influenza
viru
strain
includ
pathogen
avian
influenza
viru
ref
low
solubl
limit
abil
deliv
high
dose
vehicl
toxic
suggest
robust
protect
mous
lethal
might
obtain
newer
gener
inhibitor
improv
dmpk
higher
solubl
nontox
deliveri
system
importantli
compound
show
ad
toxic
beyond
vehicl
measur
extens
blood
chemistri
profil
liver
toxic
panel
modifi
irwin
neurolog
measur
wide
varieti
paramet
autonom
nervou
system
somatomotor
system
promis
result
led
investig
mechan
pld
inhibit
promot
surviv
influenza
viru
infect
vivo
prevent
product
infect
vitro
note
multipl
stage
viru
life
cycl
could
affect
pld
inhibit
use
combin
microscopi
rnai
demonstr
viral
entri
significantli
delay
prophylact
treatment
human
adenocarcinoma
alveolar
cell
true
infecti
virus
noninfecti
transferrin
uptak
indic
gener
defect
endocytosi
howev
block
complet
viru
eventu
abl
enter
cell
matur
endosom
also
affect
express
significantli
delay
compar
cell
cell
treat
vehicl
importantli
mechan
block
suffici
confer
protect
rather
hostcel
innat
immun
respons
mediat
retino
acidinduc
gene
rigi
interferonregulatori
factor
mxa
also
known
determin
rnai
requir
protect
effect
fig
delay
viru
endocytosi
permit
effici
effect
antivir
respons
limit
subsequ
product
viru
replic
novel
mechan
demonstr
potenti
broadspectrum
antivir
activ
inhibit
gave
indic
treatment
show
remark
low
toxic
although
endocytosi
slow
block
thu
permit
normal
cell
metabol
cellular
process
continu
albeit
alter
kinet
data
also
suggest
viru
exocytosi
measur
accumul
surfacetraffick
endosom
delay
probabl
mechan
similar
limit
viru
entri
effect
seem
less
strike
entri
phenotyp
continu
explor
potenti
multipl
pathway
action
inhibit
influenza
viru
replic
ongo
summari
inhibit
protect
influenza
viru
infect
delay
block
endocytosi
allow
hostcel
innat
immun
system
mount
effect
respons
influenza
viru
extend
window
antivir
activ
significantli
reduc
product
viru
replic
step
ptdoh
contribut
infect
summar
fig
hiv
gener
pathway
inhibit
protect
influenza
viru
infect
suggest
similar
efficaci
might
seen
envelop
virus
support
hypothesi
inhibitor
greatli
reduc
abil
hiv
replic
cell
surprisingli
distinct
element
mechan
suppress
hiv
influenza
viru
pld
pld
inhibit
previous
shown
block
activ
breast
cancer
vitro
assay
cell
treatment
inhibitor
reduc
extracellular
signalregul
kinas
erk
phosphoryl
cell
erk
activ
cell
stimul
requir
myc
turn
crucial
event
metabol
reprogram
occur
cell
activ
hiv
target
activ
cell
make
use
increas
metabol
store
gener
support
rapid
cell
divis
effector
consist
treatment
compound
reduc
induct
myc
cell
vitro
experi
event
occur
downstream
myc
activ
includ
induct
phosphoryl
ribosom
protein
kinas
also
reduc
deoxyribonucleotid
triphosph
dntp
store
necessari
rapid
replic
cell
expans
phase
one
key
metabol
resourc
accumul
cell
activ
metabol
reprogram
hiv
also
make
use
pool
complet
replic
establish
deplet
dntp
store
activ
cell
key
mechan
downstream
inhibit
dntp
ad
cell
shown
rescu
hiv
replic
cellbas
thu
inhibit
vitro
restrict
hiv
infect
alter
hostcel
metabol
store
disrupt
viru
life
cycl
new
therapeut
compound
hiv
increasingli
essenti
owe
emerg
resist
strain
also
unmet
need
develop
antihiv
drug
work
cn
hiv
recent
shown
local
mutat
possibl
becom
resist
convent
antiretroviru
abil
pld
inhibitor
penetr
may
provid
novel
approach
treat
otherwis
difficulttoreach
reservoir
retroviru
interestingli
pathway
role
strikingli
similar
hiv
infect
recent
describ
pld
activ
shown
promot
rna
replic
red
clover
necrot
mosaic
plant
suggest
ptdoh
modul
viru
replic
evolutionarili
conserv
pathway
signal
lipid
broad
role
infecti
process
pathogen
figur
depict
pathway
downstream
isoenzym
illustr
role
infect
process
pathogen
virus
pathway
target
therapeut
purpos
pathway
involv
signal
via
akt
connect
autophag
flux
wherea
recent
shown
modul
pyrimidin
biosynthesi
via
enzym
cad
contain
carbamoyl
aspart
synthas
aspart
transcarbamylas
dihydroorotas
domain
make
cad
potenti
target
futur
antiretrovir
although
pathway
downstream
pld
activ
exploit
virus
distinct
suggest
common
mechan
inhibitor
particular
pld
isoform
might
serv
broadspectrum
inhibitor
infect
shortterm
inhibit
particular
pld
enzym
influenc
numer
cellular
process
affect
viral
infect
replic
effici
mani
virus
even
modest
reduct
earli
replic
effici
complet
alter
subsequ
infecti
process
allow
host
success
mount
immun
balanc
effect
redund
lipid
signal
product
reaction
catalys
pld
enzym
might
explain
limit
vivo
toxic
isoformspecif
inhibitor
studi
describ
focus
mammalian
host
pld
enzym
target
disrupt
pathogen
replic
howev
bacteri
fungal
pathogen
contain
evolutionarili
distinct
pld
enzym
potenti
target
direct
antimicrobi
moreov
evid
certain
parasit
exploit
pathway
downstream
pld
bacteria
parasit
activ
pld
enzym
neutrophil
leukocyt
associ
antimicrobi
activ
phagocytosi
chemotaxi
membran
evolutionarili
older
function
bacteria
may
promot
bacteri
fit
mammalian
host
sever
intracellular
pathogen
gene
encod
protein
product
promot
virul
increas
pathogen
intern
intracellular
surviv
gene
gener
nonessenti
surviv
bacteri
strain
promot
entri
immun
evas
inhibit
hostcel
immun
defenc
pld
enzym
function
virul
factor
common
oblig
facult
intracellular
gramneg
bacteria
yersinia
pesti
caus
agent
bubon
yersinia
murin
toxin
ymt
contain
two
hkd
motif
highli
toxic
inject
ymt
involv
transmiss
pathogen
flea
requir
virul
exclus
human
pathogen
neisseria
gonorrhoea
gramneg
bacterium
caus
sexual
transmit
diseas
gonorrhoea
bacterium
invad
cervic
epitheli
cell
initi
bind
complement
receptor
initi
membran
ruffl
endocytosi
secret
kda
pld
homologu
ngpld
identifi
follow
releas
cultur
host
cell
challeng
although
mechan
secret
identifi
ngpld
shown
induc
recruit
cell
surfac
promot
cytoskelet
rearrang
facilit
infect
ngpld
known
requir
interact
human
hostcel
factor
name
kinas
sever
bacteri
pathogen
shown
express
pld
gene
function
virul
factor
includ
p
aeruginosa
legionella
monocytogen
chlamydia
trachomati
acinetobact
baumannii
among
p
aeruginosa
opportunist
pathogen
afflict
immunocompromis
individu
major
caus
hospitalacquir
infect
patient
cystic
fibrosi
particularli
suscept
chronic
infect
p
aeruginosa
infect
ultim
lead
respiratori
failur
unlik
bacteri
pld
enzym
p
aeruginosa
pld
plda
compar
larg
kda
much
higher
homolog
eukaryot
pld
enzym
bacteri
isoform
probabl
result
horizont
gene
p
aeruginosa
plda
secret
effector
type
vi
secret
system
similarli
mani
bacteri
pld
virul
factor
plda
intern
induc
chang
vesicl
traffick
host
cell
unusu
properti
catalyt
activ
stimul
polyphosphatidylinositol
may
explain
observ
local
plda
intracellular
convent
benzimidazolon
triazaspiron
seri
compound
littl
effect
p
aeruginosa
plda
like
minim
efficaci
bacteri
pld
enzym
howev
seri
desketoraloxifenebas
compound
compound
effect
inhibitor
plda
recent
may
provid
novel
pharmacolog
intervent
potent
compound
studi
raloxifen
serm
previous
identifi
direct
inhibitor
mammalian
pld
seri
analogu
oestrogen
receptor
bind
elimin
character
fig
yet
analogu
compound
retain
abil
inhibit
human
human
well
p
aeruginosa
new
compound
seri
provid
excel
start
point
develop
potent
select
inhibitor
pld
enzym
also
includ
compound
use
clinic
decad
unknowingli
suppress
activ
particular
pld
enzym
use
therapeut
dose
recent
found
certain
parasit
might
also
util
pathway
downstream
pld
illustr
vitro
experi
show
pld
inhibitor
block
prolifer
plasmodium
falciparum
one
causal
agent
malaria
toxoplasma
gondii
caus
toxoplasmosi
increas
express
pld
enzym
subcellular
misloc
alter
pld
catalyt
activ
implic
contribut
factor
sever
type
human
cancer
recent
review
examin
role
pathway
involv
cancer
progress
numer
report
directli
link
pld
enzym
transform
tumorigenesi
varieti
cancer
type
includ
brain
among
other
widespread
occurr
elev
pld
activ
express
human
cancer
suggest
connect
process
central
cellular
transform
ptdoh
signal
rtk
act
oncogen
driver
cancer
associ
activ
evid
also
downstream
signal
compon
rtkinduc
signal
rtk
epiderm
growth
factor
receptor
egfr
initi
signal
cascad
known
role
cellular
transform
includ
signal
pathway
lead
product
lipid
second
messeng
bind
hormon
epiderm
growth
factor
lead
egfr
dimer
follow
autophosphoryl
multipl
tyrosin
residu
form
bind
site
src
homolog
domain
includ
growth
factor
receptorbound
protein
subunit
phosphoinositid
bind
domain
import
step
catalyt
activ
gener
ptdoh
step
also
facilit
recruit
guanin
nucleotideexchang
protein
sonofsevenless
so
event
promot
feedforward
mechan
activ
ra
gtpase
turn
lead
rala
gtpase
activ
modul
pld
semin
observ
vivo
tumour
format
hrasdriven
cancer
cell
block
coexpress
catalyt
inact
form
ref
compel
report
boost
search
isoenzymeselect
smallmolecul
inhibitor
pld
activ
effect
inhibit
hrasdriven
tumour
format
probabl
repres
one
sever
key
role
rasmedi
oncogenesi
role
process
reiter
recent
observ
novel
oncogen
act
downstream
pld
catalyt
activ
promot
mammari
epitheli
cell
transform
via
rasdepend
egfrdepend
one
hallmark
cancer
elev
use
glucos
via
glycolysi
histor
thought
primarili
respons
higher
energi
need
cancer
cell
rel
normal
cell
appreci
cancer
cell
obtain
cellular
energi
oxid
recent
evid
suggest
rapidli
divid
cell
dramat
growth
rate
use
glycolyt
pathway
mean
biosynthes
lipid
amino
acid
intermedi
molecul
may
view
metabol
currenc
dysfunct
regul
signal
pathway
frequent
caus
abnorm
metabol
rate
cancer
cell
phenomenon
higher
metabol
rate
cancer
cell
rel
healthi
cell
prefer
cancer
cell
use
aerob
glycolysi
known
warburg
effect
recent
insight
cancer
cell
metabol
led
develop
smallmolecul
inhibitor
disrupt
cellular
pathway
shown
least
partial
modul
essenti
pathway
involv
metabol
smallmolecul
inhibitor
pld
isoenzym
may
therefor
better
toler
convent
chemotherapeut
agent
partial
suppress
stressmedi
respons
metabol
pathway
oppos
shut
mani
extracellular
signal
hormon
stimul
acut
remov
nutrient
upregul
product
certain
metabol
speci
recent
demonstr
vitro
inhibitor
inhibitor
transient
reduc
pyrimidin
biosynthesi
human
glioblastomaderiv
detail
comparison
parallel
metabolom
phosphoproteom
analys
suggest
effect
mediat
modul
enzym
cad
act
downstream
mtor
consist
previou
report
demonstr
modul
mtor
pathway
pldgener
may
explain
pld
inhibitor
via
indirect
effect
cad
function
activ
cancer
cell
see
also
fig
sinc
first
descript
mammalian
pld
activ
rat
brain
role
pld
enzym
cn
intens
appreci
signaldepend
activ
pld
enzym
observ
divers
array
brainderiv
neuronderiv
cell
exampl
glial
cell
primari
neuron
glioma
neuroblastoma
cell
variou
neurotransmitt
neuromodul
shown
activ
pld
cn
display
distinct
differenti
distribut
function
numer
studi
past
year
begun
delin
potenti
isoenzym
repres
therapeut
target
cn
disord
previou
effort
reli
overexpress
either
catalyt
activ
inact
form
cell
mice
particular
pld
isoenzym
genet
delet
use
rnai
knock
individu
pld
isoform
effort
discern
discret
role
brain
found
upon
induc
experiment
autoimmun
encephalomyel
eae
rat
express
increas
spinal
cord
eae
studi
suggest
role
autoimmun
cn
inflamm
involv
activ
macrophag
astrocyt
format
eae
lesion
suggest
inhibitor
possibl
therapeut
treatment
multipl
sclerosi
neuroinflammatori
diseas
also
shown
upregul
spinal
cord
rat
clip
compress
injuri
suggest
inhibitor
might
also
use
treatment
spinal
cord
addit
implic
arteri
thrombosi
ischaem
mice
shown
display
impair
integrin
activ
defect
glycoprotein
aggreg
format
led
protect
thrombosi
ischaem
brain
injuri
without
increas
bleed
find
recapitul
studi
use
pld
inhibitor
fipi
demonstr
pharmacolog
inhibit
pld
also
reduc
occlus
thrombosi
led
smaller
infarct
size
improv
motor
cognit
among
excit
discoveri
relev
cn
disord
identif
pld
potenti
therapeut
target
alzheim
diseas
studi
report
upregul
mitochondri
fraction
brain
tissu
patient
alzheim
diseas
region
amyloid
precursor
protein
app
bind
stimul
contribut
recent
interest
develop
lead
compound
use
mice
nonoverlap
role
pathogenesi
alzheim
diseas
demonstr
along
potenti
therapeut
target
overexpress
biochem
studi
show
regul
traffick
app
assembl
complex
via
direct
interact
presenilin
vivo
experi
shown
requir
synaptotox
action
ablat
rescu
memori
deficit
promot
synapt
protect
swapp
mice
despit
high
final
genomewid
associ
studi
identifi
rare
variant
doubl
risk
lateonset
alzheim
diseas
load
howev
less
individu
load
carri
highli
express
brain
region
prone
alzheim
diseas
cortex
hippocampu
express
significantli
lower
level
neuron
brain
patient
alzheim
diseas
control
unfortun
unknown
whether
exist
pldinhibitor
chemotyp
modul
catalyt
activ
precis
biolog
function
human
cn
also
unknown
also
noteworthi
sever
recent
report
question
initi
find
regard
molecular
associ
rare
allel
occurr
earli
onset
alzheim
next
gener
potent
isoenzymeselect
highli
brainpenetr
pld
inhibitor
avail
next
year
provid
promis
advanc
target
pld
isoenzym
multipl
cn
disord
identifi
new
target
cellular
lipid
signal
cascad
lipid
signal
metabolit
intermedi
provid
potenti
target
therapeut
intervent
cancer
infecti
diseas
cn
disord
note
product
newli
synthes
ptdoh
consequ
infectioninduc
activ
cellular
signal
pathway
may
underreport
ptdoh
accumul
may
highli
transient
owe
rapid
flux
lipid
speci
enzym
convert
ptdoh
dag
lysophosphatid
acid
lysoptdoh
constitu
kennedi
pathway
see
fig
investig
hcmvinfect
cell
line
suggest
ptdoh
gener
respons
infect
occur
via
de
novo
biosynthesi
result
activ
pld
howev
observ
increas
ptdoh
mass
follow
infect
cell
line
influenza
viru
effect
reduc
treatment
isoformselect
pld
lead
us
propos
ptdoh
hypothesi
infect
postul
ptdoh
accumul
may
compon
infect
broadli
relev
viral
bacteri
fungal
pathogen
moreov
although
role
pld
enzym
cancer
infecti
neurodegen
diseas
undoubtedli
complex
multifacet
tempt
specul
reflect
share
role
intermedi
metabol
diseas
recent
discoveri
influenc
dntp
store
effect
mtor
provid
new
insight
smallmolecul
inhibitor
affect
retrovir
replic
sinc
abnorm
mtor
signal
also
occur
earli
stage
alzheim
cancer
inhibitor
may
similar
mechan
action
differ
condit
moreov
signal
axi
seem
common
node
import
sever
pathogen
process
pathway
lie
upstream
beclin
key
compon
regul
cellular
illustr
share
role
lipid
metabol
cancer
infect
cn
condit
target
distinct
pld
isoenzym
may
broad
therapeut
potenti
like
smallmolecul
inhibitor
pld
isoenzym
test
efficaci
diseas
current
unsatisfactori
standard
care
absenc
toxic
effect
anim
model
highli
encourag
mani
detail
remain
discov
role
pld
isoenzym
develop
multipl
chemic
scaffold
function
smallmolecul
isoenzymeselect
inhibitor
pld
provid
import
step
defin
therapeut
valu
target
mammalian
bacteri
form
pld
essenti
continu
extend
quantit
measur
ptdoh
metabol
product
variou
diseas
state
identifi
whether
sourc
diseaseassoci
alter
level
ptdoh
misregul
enzym
involv
product
import
signal
lipid
current
advanc
mass
spectrometrybas
metabolom
lipidom
phosphoproteom
analys
new
particip
establish
signal
metabol
pathway
reveal
provid
excit
opportun
therapeut
target
key
question
answer
whether
ptdoh
predominantli
serv
biophys
role
exampl
entri
egress
virus
whether
primarili
affect
nuclear
transcript
event
innat
immun
process
also
exploit
bacteria
parasit
structur
role
lipid
compon
viral
envelop
also
remain
area
ptdoh
gener
occur
via
de
novo
synthesi
kennedi
pathway
pld
pathway
pathway
need
interrog
experiment
pathogen
microorgan
allow
determin
whether
inhibitor
pathway
could
serv
broadspectrum
antiinfecti
agent
crucial
need
drugresist
strain
continu
emerg
